News headlines about Biostage (NASDAQ:BSTG) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biostage earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.5561165311508 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern’s rankings:

Biostage (BSTG) traded up 9.11% during trading on Friday, hitting $0.34. 1,545,368 shares of the company’s stock traded hands. The stock’s market cap is $13.24 million. Biostage has a 12 month low of $0.22 and a 12 month high of $1.42. The company’s 50 day moving average is $0.43 and its 200-day moving average is $0.37.

Biostage (NASDAQ:BSTG) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by $0.03. On average, analysts predict that Biostage will post ($0.42) earnings per share for the current year.

Separately, Maxim Group reissued a “hold” rating on shares of Biostage in a research report on Monday, August 7th.

TRADEMARK VIOLATION NOTICE: “Biostage (BSTG) Earning Somewhat Positive Press Coverage, Study Finds” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at

In related news, insider Saverio Lafrancesca acquired 100,000 shares of the stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average price of $0.37 per share, for a total transaction of $37,000.00. Following the completion of the transaction, the insider now directly owns 293,998 shares in the company, valued at $108,779.26. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Biostage Company Profile

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

Receive News & Stock Ratings for Biostage Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc. and related stocks with our FREE daily email newsletter.